Merck & Co Inc.
(NYSE:MRK) on Wednesday released topline data from the Phase 3 KEYNOTE‑C93 trial of Keytruda (pembrolizumab).
Phase 3 Trial Meets Primary Progression-Free Survival Goal The trial met its primary endpoint of progression-free survival (PFS) for mismatch repair-deficient (dMMR) advanced or recurrent endometrial cancer patients who had not previously received systemic chemotherapy or who experienced recurrence more than six months after completing prior adjuvant therapy.
Keytruda is the first and only PD-1 inhibitor to show a statistically significant and clinically meaningful improvement in PFS as monotherapy compared to platinum doublet chemotherapy for these patients in a Phase 3 trial.
Read Also: Merck, AbbVie Hit With Congressional Probe Over China Drug Trials: Report At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, a trend toward improvement in overall survival (OS), the trial’s other primary endpoint, was observed for Keytruda.
